BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verzoni E, Ratta R, Grassi P, Salvioni R, Stagni S, Montone R, Fucà G, Cappelletti V, Reduzzi C, De Giorgi U, Procopio G. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery. Tumori 2018;104:401-5. [DOI: 10.5301/tj.5000699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Cappelletti V, Verzoni E, Ratta R, Vismara M, Silvestri M, Montone R, Miodini P, Reduzzi C, Claps M, Sepe P, Daidone MG, Procopio G. Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression. Int J Mol Sci 2020;21:E1475. [PMID: 32098246 DOI: 10.3390/ijms21041475] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Cimadamore A, Aurilio G, Nolé F, Massari F, Scarpelli M, Santoni M, Lopez-Beltran A, Cheng L, Montironi R. Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells 2020;9:E1495. [PMID: 32575429 DOI: 10.3390/cells9061495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Biles MJ, Patel HD, Allaf ME. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors. Urol Clin North Am 2020;47:359-70. [PMID: 32600537 DOI: 10.1016/j.ucl.2020.04.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hishida T, Masai K, Kaseda K, Asakura K, Asamura H. Debulking surgery for malignant tumors: the current status, evidence and future perspectives. Jpn J Clin Oncol 2021:hyab107. [PMID: 34254145 DOI: 10.1093/jjco/hyab107] [Reference Citation Analysis]
5 Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, Meng W, Dewal N, Milbury C, Clark T, Donahue A, Stover D, Kennedy M, Dacpano-Komansky J, Burns C, Vietz C, Alexander B, Hegde P, Dennis L. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One 2020;15:e0237802. [PMID: 32976510 DOI: 10.1371/journal.pone.0237802] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
6 Pilié PG, Jonasch E. Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. Kidney Cancer 2017;1:57-64. [PMID: 30334005 DOI: 10.3233/KCA-170009] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Westerman ME, Shapiro DD, Tannir NM, Campbell MT, Matin SF, Karam JA, Wood CG. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int 2020;126:745-53. [PMID: 32623821 DOI: 10.1111/bju.15160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mason RJ, Wood L, Kapoor A, Basappa N, Bjarnason G, Boorjian SA, Breau RH, Cagiannos I, Jewett MAS, Karakiewicz PI, Kassouf W, Kollmannsberger C, Lalani AA, Lattouf JB, Lavallée LT, Pautler S, Power N, Richard P, So A, Tanguay S, Rendon RA. Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Can Urol Assoc J 2019;13:166-74. [PMID: 31199235 DOI: 10.5489/cuaj.5786] [Cited by in F6Publishing: 4] [Reference Citation Analysis]